{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":12,"podcast":6,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01996267\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TRAIN-2","nct_id":"NCT01996267","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=train-2-nct01996267. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TRAIN-2","arms":[{"description":"Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days","label":"FEC-T +Pertuzumab","type":"ACTIVE_COMPARATOR"},{"description":"Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days","label":"PTC+Pertuzumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["Roche Pharma AG","Borstkanker Onderzoek Groep"],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["Breast Cancer","HER2 Positive"],"enrollment":{"count":437,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"PTC+Pertuzumab","type":"DRUG"},{"name":"FEC-T+Pertuzumab","type":"DRUG"}],"last_update":"2024-03-29","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2018-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of patients with pathological complete response","timeFrame":"at week 30"}],"references":[{"citation":"van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371.","pmid":"34014249","type":"DERIVED"},{"citation":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentje VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6.","pmid":"30413379","type":"DERIVED"}],"start_date":{"date":"2013-12"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","url":"https://clinicaltrials.gov/study/NCT01996267"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/train-2-nct01996267"}